Read/Post Comments (0) | Recommended this article (0)
Please login to Zacks.com or register to post a comment.
Zacks' 7 Best Stocks
for June, 2013
FREE Report for Zacks.com
Visitors Only
Visitors Only
They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.
Today, you can see them free.
- Latest News
- Most Popular
- Hitting Home Runs & Grand Slams, Not Loud Outs
- RTI: Do Stocks Tank When QE Ends?
- 3 Top-Ranked Consumer ETFs to Buy Now
- This Week's Aggressive Growth Stocks
- Who Wants to Keep "Too Big to Fail" Alive?
- Debt-Ceiling Alarm Bell Tolls
- Avoid These 3 Eurozone ETFs This Summer
- RTI: When Will We Finally See a Pullback?
- Top Stocks with Big Potential Catch-Up Moves
- AWS 5/23: Is the Market Over-Reacting?
- PFP 5/23: Do No Harm
Recent Quotes
| No Recent Quote currently available |
My Portfolio
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
More Zacks Resources
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
Zacks #1 Stocks on the Move 05/23/2013
| Company Name | Symbol | %Change |
|---|---|---|
| WESTELL TECH | WSTL | 5.13% |
| MAXWELL TECH | MXWL | 4.55% |
| BLOOMIN' | BLMN | 3.25% |
| ALLIANCE FIB | AFOP | 2.44% |
| MERITAGE HOM | MTH | 1.82% |
Quick Links
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
Pluristem Therapeutics, Inc. ( PSTI - Snapshot Report ) recently announced that it has filed documents with the US Food and Drug Administration (FDA) seeking orphan drug status for using its PLacental eXpanded (PLX) cells to treat patients suffering from aplastic anemia.
Aplastic anemia refers to a rare, serious disorder resulting from the destruction of blood-forming stem cells (hematopoietic stem cells, or HSCs) in the bone marrow. We note that in normal circumstances, HSCs develop into only red blood cells, white blood cells and platelets. However, all blood types are deficient in patients suffering from aplastic anemia.
In such cases, the patients are either supported with blood transfusions ahead of a bone marrow transplant or with drugs that cause the immune system to be suppressed. Pluristem stated in its press release that the US market for bone marrow transplants (including patients suffering from aplastic anemia) is worth approximately $1.3 billion annually.
We note that on being provided with orphan drug status by the FDA the PLX cell therapy, for treating aplastic anemia patients, will enjoy multiple benefits including seven years of marketing exclusivity (from the day the candidate is cleared by the FDA) in the US for the indication.
We remind investors that Pluristem enjoys orphan drug status for using PLX cells to treat patients suffering from Buerger's disease since August 2011. The disease results in inflammation and clotting of blood vessels thereby reducing the flow of blood in these areas.
Our Recommendation
We currently have a Neutral recommendation on Pluristem. The stock carries a Zacks #3 Rank (Hold rating) in the short run.
Read the full Snapshot Report on PSTI